News &amp; Updates

Using hydrochlorothiazide (HCTZ) for longer durations and in higher cumulative doses increases the risks for keratinocyte carcinoma and melanoma, reveals a study.

17 Aug 2023

PPI exposure can make children susceptible to serious infections

The use of proton pump inhibitors (PPIs) appears to pose heightened risks of serious infections in young children, according to a study.

Relugolix combo reduces dysmenorrhea, NMPP in premenopausal women

17 Aug 2023 by

The use of relugolix 40 mg in combination with oestradiol 1 mg and norethisterone acetate 0.5 mg (relugolix combination therapy [relugolix-CT]) significantly reduced dysmenorrhea and nonmenstrual pelvic pain (NMPP) in premenopausal women with endometriosis who received prior hormonal treatment, according to a post hoc analysis of two phase III trials presented at ESHRE 2023.

Colistin use ups mortality risk in solid organ transplant recipients

Mortality increases threefold when using colistin to treat infections in liver transplant recipients and by 5 percentage points in renal transplant recipients, a study has shown.

Demedicalized delivery of PrEP possible, improves access

A peer-led demedicalized delivery of same-day HIV pre-exposure prophylaxis (PrEP) in various community centres is feasible, suggests a Philippines study presented at the recent IAS 2023.

16 Aug 2023

Meeting gender-affirming needs tied to accessing HIV services among transgender people

Having met gender-affirming care needs among transgender people is associated with accessing HIV-related services in a community-led clinic, as shown in a Philippines study presented at IAS 2023.

16 Aug 2023

Dapagliflozin cuts risk of total HF events, CV deaths in HF patients

In a prespecified analysis of the DELIVER* study, the sodium glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin reduced the rate of total** heart failure (HF) events or cardiovascular (CV) deaths in HF patients with mildly reduced or preserved ejection fraction (HFmrEF or HFpEF).

16 Aug 2023

Chemo-free anti-ERBB2 therapy viable in ERBB2-positive MBC

In the treatment of ERBB2-positive metastatic breast cancer (MBC), the use of pertuzumab plus trastuzumab alone in the first-line setting and delaying chemotherapy may be a reasonable option for some patients, with the treatment strategy not compromising overall survival (OS) despite a much shorter progression-free survival (PFS), as shown in a study.

16 Aug 2023

Linzagolix promising for endometriosis-associated pain

Once-daily treatment with linzagolix, a novel, oral GnRH* antagonist, with or without add-back therapy (ABT), reduces dysmenorrhoea and nonmenstrual pelvic pain (NMPP), among women with endometriosis, according to the EDELWEISS 3 trial presented at ESHRE 2023.